Virtus ETF Advisers’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Virtus ETF Advisers’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-9,432	Closed	-$558K	–	185
2016 Q4	$558K	Buy	+9,432	New	+$582K	0.17%	90

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Virtus ETF Advisers's XBI Position: Q1 2017 in Review

Virtus ETF Advisers sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2017, closing a stake of 9,432 shares — an estimated $558K sold.

Virtus ETF Advisers first reported a position in XBI in Q4 2016 and held it in 1 quarter. The position peaked at $558K in Q4 2016. 292 funds tracked by Wall St. Rank hold XBI as of Q1 2017.

Virtus ETF Advisers reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2017 after selling out during the quarter.
Virtus ETF Advisers sold 9,432 State Street SPDR S&P Biotech ETF shares in Q1 2017, an estimated $558K.
Virtus ETF Advisers first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and held it in 1 quarter.
Virtus ETF Advisers's State Street SPDR S&P Biotech ETF position peaked at $558K in Q4 2016.
292 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2017.

Based on Virtus ETF Advisers's 13F filing for Q1 2017, filed 15 May 2017.